fluoxetine has been researched along with Schizophrenia in 71 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
Schizophrenia: A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Significant weight gain is a side effect associated with olanzapine treatment in some patients." | 9.10 | Treatment of weight gain with fluoxetine in olanzapine-treated schizophrenic outpatients. ( Bogenschutz, M; Bustillo, JR; Hammond, R; Keith, S; Lauriello, J; Parker, K; Rowland, L, 2003) |
| "First-episode hospitalized schizophrenia patients (N=30) were randomly assigned in an 8-week double-blind study of olanzapine, 10 mg/day, coadministered with either fluoxetine, 20 mg/day (N=15), or placebo (N=15)." | 9.10 | Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition. ( Fuchs, C; Gil-Ad, I; Maayan, R; Pashinian, A; Poyurovsky, M; Schneidman, M; Weizman, A, 2002) |
| "The effect of fluoxetine on the steady-state plasma concentrations of risperidone and its active metabolite 9-hydroxyrisperidone (9-OH-risperidone) was evaluated in 10 patients with schizophrenia or schizoaffective disorder." | 7.71 | Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction. ( Ancione, M; Avenoso, A; Gatti, G; Madia, A; Perucca, E; Scordo, MG; Spina, E, 2002) |
| "Case 2 was a female with schizoaffective disorder without a history of NMS." | 6.52 | Atypical neuroleptic malignant syndrome in patients treated with aripiprazole and clozapine: a case-series study and short review. ( Chang, CH; Chang, YC; Chen, YW; Cheng, YS; Chung, W; Tseng, PT; Wang, HY; Wu, CK, 2015) |
| "There is low-certainty evidence to suggest that metformin may be effective in preventing weight gain." | 5.22 | Pharmacological interventions for prevention of weight gain in people with schizophrenia. ( Agarwal, SM; Ahsan, ZA; Cohn, T; Duncan, MJ; Faulkner, GEJ; Hahn, M; Lockwood, JT; Remington, G; Stogios, N; Takeuchi, H; Taylor, VH, 2022) |
| "Significant weight gain is a side effect associated with olanzapine treatment in some patients." | 5.10 | Treatment of weight gain with fluoxetine in olanzapine-treated schizophrenic outpatients. ( Bogenschutz, M; Bustillo, JR; Hammond, R; Keith, S; Lauriello, J; Parker, K; Rowland, L, 2003) |
| "The effects of fluoxetine and imipramine on the pharmacokinetics and nonpsychiatric side effect profile of quetiapine fumarate were investigated in 26 patients with schizophrenia, schizoaffective disorder, or bipolar disorder in a multicenter, two-period, multiple-dose, open-label, randomized trial." | 5.10 | Effect of fluoxetine and imipramine on the pharmacokinetics and tolerability of the antipsychotic quetiapine. ( Alva, G; Arvanitis, LA; Carreon, D; Kalali, A; Potkin, SG; Thyrum, PT; Yeh, C, 2002) |
| "First-episode hospitalized schizophrenia patients (N=30) were randomly assigned in an 8-week double-blind study of olanzapine, 10 mg/day, coadministered with either fluoxetine, 20 mg/day (N=15), or placebo (N=15)." | 5.10 | Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition. ( Fuchs, C; Gil-Ad, I; Maayan, R; Pashinian, A; Poyurovsky, M; Schneidman, M; Weizman, A, 2002) |
| "Mean ratings of positive and negative symptoms and depression significantly improved in nine treatment-resistant schizophrenic patients who completed a 6-week open trial of fluoxetine added to their neuroleptics." | 5.06 | Trial of fluoxetine added to neuroleptics for treatment-resistant schizophrenic patients. ( Brotman, AW; Goff, DC; McCormick, S; Waites, M, 1990) |
| " The three case studies are (1) bupropion versus nicotine replacement therapy for smoking cessation, (2) risperidone versus haloperidol for schizophrenia, and (3) fluoxetine versus imipramine for depressive disorders." | 4.84 | Adjusted indirect comparison may be less biased than direct comparison for evaluating new pharmaceutical interventions. ( Harvey, I; Lilford, R; Song, F, 2008) |
| " Subsequently, density of [(3)H]LY341495 binding was measured in BA24(anterior cingulate cortex), BA17(visual cortex) and BA46(dorsolateral prefrontal cortex) from subjects with MDD, Bipolar Disorder(BPD), Schizophrenia(SCZ), and controls, as well as rats treated with imipramine (20mg/kg), fluoxetine (10mg/kg), or vehicle." | 3.83 | Lower [3H]LY341495 binding to mGlu2/3 receptors in the anterior cingulate of subjects with major depressive disorder but not bipolar disorder or schizophrenia. ( Dean, B; Gibbons, A; Hopper, S; McOmish, CE; Pavey, G; Scarr, E; Udawela, M, 2016) |
| "Since the prefrontal cortex (PFC) is thought to play an important role in depression and schizophrenia, we studied the effects of fluoxetine and olanzapine on PFC neurons in rats using extracellular, in vivo recordings." | 3.72 | Electrophysiological effects of acute and chronic olanzapine and fluoxetine in the rat prefrontal cortex. ( Gronier, BS; Rasmussen, K, 2003) |
| "The effect of fluoxetine on the steady-state plasma concentrations of risperidone and its active metabolite 9-hydroxyrisperidone (9-OH-risperidone) was evaluated in 10 patients with schizophrenia or schizoaffective disorder." | 3.71 | Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction. ( Ancione, M; Avenoso, A; Gatti, G; Madia, A; Perucca, E; Scordo, MG; Spina, E, 2002) |
| "A 26-year-old man with schizophrenia, disorganised type, and depression, developed severe tardive dyskinesia during treatment with risperidone and fluoxetine." | 3.70 | [Severe tardive dyskinesia during treatment with risperidone and fluoxetine]. ( Dubbelman, YD; Heeringa, M; Thung, FH, 1998) |
| "As fluoxetine is a potent inhibitor of cytochrome P450 (CYP) 2D6, these results also provide indirect evidence for an involvement of CYP2D6 in the metabolism of haloperidol." | 2.68 | Interaction between fluoxetine and haloperidol: pharmacokinetic and clinical implications. ( Avenoso, A; Campo, G; Caputi, AP; Facciolă, G; Ferlito, M; Perucca, E; Spinà, E; Zuccaro, P, 1997) |
| "Fluoxetine treatment did not influence positive schizophrenic symptoms, while it induced a slight, but statistically significant, decrease (p < 0." | 2.67 | Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenic patients. ( Ancione, M; Caputi, AP; De Domenico, P; Di Rosa, AE; Gitto, C; Longobardo, N; Ruello, C; Spina, E, 1994) |
| "With valproic acid, there was a minor increase in total clozapine metabolites, which was even less with dose correction." | 2.67 | Serum concentrations of clozapine and its major metabolites: effects of cotreatment with fluoxetine or valproate. ( Baldessarini, RJ; Centorrino, F; Flood, JG; Frankenburg, FR; Kando, J; Puopolo, PR; Volpicelli, SA, 1994) |
| "Case 2 was a female with schizoaffective disorder without a history of NMS." | 2.52 | Atypical neuroleptic malignant syndrome in patients treated with aripiprazole and clozapine: a case-series study and short review. ( Chang, CH; Chang, YC; Chen, YW; Cheng, YS; Chung, W; Tseng, PT; Wang, HY; Wu, CK, 2015) |
| "Fluoxetine (20 mg/day) was added for 7-10 days to stable doses of haloperidol given to eight psychotic patients." | 1.28 | Elevation of plasma concentrations of haloperidol after the addition of fluoxetine. ( Baldessarini, RJ; Brotman, AW; Goff, DC; Midha, KK; Waites, M, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.41) | 18.7374 |
| 1990's | 41 (57.75) | 18.2507 |
| 2000's | 18 (25.35) | 29.6817 |
| 2010's | 10 (14.08) | 24.3611 |
| 2020's | 1 (1.41) | 2.80 |
| Authors | Studies |
|---|---|
| Agarwal, SM | 1 |
| Stogios, N | 1 |
| Ahsan, ZA | 1 |
| Lockwood, JT | 1 |
| Duncan, MJ | 1 |
| Takeuchi, H | 1 |
| Cohn, T | 1 |
| Taylor, VH | 1 |
| Remington, G | 1 |
| Faulkner, GEJ | 1 |
| Hahn, M | 1 |
| Tseng, PT | 1 |
| Chang, YC | 1 |
| Chang, CH | 1 |
| Wang, HY | 1 |
| Cheng, YS | 1 |
| Wu, CK | 1 |
| Chen, YW | 1 |
| Chung, W | 1 |
| Jayarajan, RN | 1 |
| Shere, S | 1 |
| Sutar, R | 1 |
| Karmani, S | 1 |
| Reddi, VS | 1 |
| Kesavan, M | 1 |
| Viswanath, B | 1 |
| Jain, S | 1 |
| McOmish, CE | 1 |
| Pavey, G | 1 |
| Gibbons, A | 1 |
| Hopper, S | 1 |
| Udawela, M | 1 |
| Scarr, E | 1 |
| Dean, B | 1 |
| Figueiredo, T | 1 |
| Segenreich, D | 1 |
| Mattos, P | 1 |
| Mowla, A | 1 |
| Dastgheib, SA | 1 |
| Ebrahimi, AA | 1 |
| Pani, A | 1 |
| Yang, FW | 1 |
| Liang, CS | 1 |
| Korkmaz, S | 1 |
| Işik, U | 1 |
| Korkmaz, H | 1 |
| Takashima, N | 1 |
| Odaka, YS | 1 |
| Sakoori, K | 1 |
| Akagi, T | 1 |
| Hashikawa, T | 1 |
| Morimura, N | 1 |
| Yamada, K | 1 |
| Aruga, J | 1 |
| Richtand, NM | 1 |
| Ahlbrand, R | 1 |
| Horn, P | 1 |
| Tambyraja, R | 1 |
| Grainger, M | 1 |
| Bronson, SL | 1 |
| McNamara, RK | 1 |
| Raghunath, A | 1 |
| Andrade, C | 1 |
| Spina, E | 4 |
| Avenoso, A | 3 |
| Scordo, MG | 1 |
| Ancione, M | 2 |
| Madia, A | 1 |
| Gatti, G | 1 |
| Perucca, E | 3 |
| Safranko, I | 1 |
| Bustillo, JR | 1 |
| Lauriello, J | 1 |
| Parker, K | 1 |
| Hammond, R | 1 |
| Rowland, L | 1 |
| Bogenschutz, M | 1 |
| Keith, S | 1 |
| Gronier, BS | 1 |
| Rasmussen, K | 1 |
| Shim, JC | 1 |
| Kelly, DL | 1 |
| Kim, YH | 1 |
| Yoon, YR | 1 |
| Park, JH | 1 |
| Shin, JG | 1 |
| Conley, RR | 1 |
| Kordon, A | 1 |
| Broocks, A | 1 |
| Hohagen, F | 1 |
| Levy, E | 1 |
| Margolese, HC | 1 |
| Sultan, S | 1 |
| Chouinard, G | 1 |
| Sayeed Khan, MN | 1 |
| Arshad, N | 1 |
| Ullah, N | 1 |
| Silver, H | 1 |
| Mackin, P | 1 |
| Young, AH | 1 |
| Theleritis, CG | 1 |
| Papadimitriou, GN | 1 |
| Papageorgiou, CC | 1 |
| Dikeos, DG | 1 |
| Masdrakis, V | 1 |
| Kostoulas, C | 1 |
| Psarros, C | 1 |
| Soldatos, CR | 1 |
| Ozturk, S | 1 |
| Ozsenel, EB | 1 |
| Kazancioglu, R | 1 |
| Turkmen, A | 1 |
| Song, F | 1 |
| Harvey, I | 1 |
| Lilford, R | 1 |
| Enna, SJ | 1 |
| Campbell, M | 1 |
| Cueva, JE | 1 |
| Rothschild, AJ | 1 |
| Goff, DC | 3 |
| Midha, KK | 2 |
| Sarid-Segal, O | 1 |
| Hubbard, JW | 1 |
| Amico, E | 1 |
| Bellino, S | 1 |
| Barzega, G | 1 |
| Bogetto, F | 1 |
| Maina, G | 1 |
| Ravizza, L | 1 |
| D'Souza, DC | 1 |
| Bennett, A | 1 |
| Abi-Dargham, A | 1 |
| Krystal, JH | 1 |
| De Domenico, P | 1 |
| Ruello, C | 1 |
| Longobardo, N | 1 |
| Gitto, C | 1 |
| Di Rosa, AE | 1 |
| Caputi, AP | 3 |
| Kulik, FA | 1 |
| Wilbur, R | 1 |
| Bacher, NM | 2 |
| Sanzone, MM | 1 |
| Kaup, B | 1 |
| Caroli, F | 2 |
| Baldacci-Epinette, C | 1 |
| Ribeyre, P | 1 |
| Eales, MJ | 1 |
| Layeni, AO | 1 |
| Eggert, AE | 1 |
| Crismon, ML | 1 |
| Dorson, PG | 1 |
| Sewell, DD | 1 |
| Lopez, WM | 1 |
| Paulsen, J | 1 |
| Gilbert, P | 1 |
| Hwang, MY | 2 |
| Martin, AM | 1 |
| Lindenmayer, JP | 2 |
| Stein, D | 2 |
| Hollander, E | 2 |
| Centorrino, F | 2 |
| Baldessarini, RJ | 3 |
| Kando, J | 2 |
| Frankenburg, FR | 2 |
| Volpicelli, SA | 2 |
| Puopolo, PR | 1 |
| Flood, JG | 2 |
| Tejera, CA | 1 |
| Mayerhoff, DJ | 1 |
| Safferman, AZ | 1 |
| Ramos-Lorenzi, JR | 1 |
| Simeon, D | 1 |
| Ninan, PT | 1 |
| Shelton, S | 1 |
| Patel, B | 1 |
| Tandon, R | 1 |
| Daniel, DG | 1 |
| Smith, K | 1 |
| Hyde, T | 1 |
| Egan, M | 1 |
| Maes, M | 1 |
| De Meester, I | 1 |
| Scharpe, S | 1 |
| Desnyder, R | 1 |
| Ranjan, R | 1 |
| Meltzer, HY | 1 |
| Buchanan, RW | 2 |
| Kirkpatrick, B | 2 |
| Bryant, N | 1 |
| Ball, P | 1 |
| Breier, A | 1 |
| Campo, G | 1 |
| Facciolă, G | 2 |
| Ferlito, M | 1 |
| Zuccaro, P | 1 |
| Purdon, SE | 1 |
| Snaterse, M | 1 |
| Fabrazzo, M | 1 |
| Monteleone, P | 1 |
| Maj, M | 1 |
| Dubbelman, YD | 1 |
| Thung, FH | 1 |
| Heeringa, M | 1 |
| Lane, HY | 2 |
| Liu, CC | 1 |
| Chang, WH | 2 |
| Mahendran, R | 1 |
| Mottard, JP | 1 |
| de la Sablonnière, JF | 1 |
| Aymard, N | 1 |
| Viala, A | 1 |
| Baldacci, C | 1 |
| Smagghe, PO | 1 |
| Vacheron, MN | 1 |
| Lu, ML | 1 |
| Arango, C | 1 |
| Lund, BC | 1 |
| Perry, PJ | 1 |
| Miller, DD | 1 |
| Potkin, SG | 1 |
| Thyrum, PT | 1 |
| Alva, G | 1 |
| Carreon, D | 1 |
| Yeh, C | 1 |
| Kalali, A | 1 |
| Arvanitis, LA | 1 |
| Poyurovsky, M | 1 |
| Pashinian, A | 1 |
| Gil-Ad, I | 1 |
| Maayan, R | 1 |
| Schneidman, M | 1 |
| Fuchs, C | 1 |
| Weizman, A | 1 |
| Cassady, SL | 1 |
| Thaker, GK | 1 |
| Brewerton, TD | 1 |
| Shannon, M | 1 |
| Baker, RW | 1 |
| Ruskin, P | 1 |
| Brotman, AW | 2 |
| Waites, M | 2 |
| McCormick, S | 1 |
| Goldman, MB | 2 |
| Janecek, HM | 2 |
| Kim, SW | 1 |
| Dysken, MW | 1 |
| Vakharia, M | 1 |
| Kanofsky, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Comparison of Bupropion SR and Placebo for Smoking Cessation[NCT00176449] | Phase 4 | 52 participants (Actual) | Interventional | 2001-04-30 | Completed | ||
| Alterations in mRNA and Protein Expression in Human Peripheral Mononuclear Blood Cells (PMC) of Schizophrenia Patients Treated With Fluvoxamine Augmentation of Antipsychotics: Relationship to Clinical Symptoms and Cognitive Function[NCT00645580] | 15 participants (Anticipated) | Interventional | 2008-04-30 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 reviews available for fluoxetine and Schizophrenia
| Article | Year |
|---|---|
Pharmacological interventions for prevention of weight gain in people with schizophrenia.
Topics: Antipsychotic Agents; Betahistine; Famotidine; Fluoxetine; Humans; Melatonin; Metformin; Nausea; Niz | 2022 |
Atypical neuroleptic malignant syndrome in patients treated with aripiprazole and clozapine: a case-series study and short review.
Topics: Adult; Aripiprazole; Clozapine; Creatine Kinase; Dose-Response Relationship, Drug; Drug Substitution | 2015 |
[Obsessive-compulsive disorders in general practice. How the obsessive-compulsive neurotic is revealed by skin and hair].
Topics: Adolescent; Adult; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Antidepressive Age | 2003 |
Selective serotonin re-uptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia.
Topics: Antidepressive Agents, Second-Generation; Antipsychotic Agents; Chemotherapy, Adjuvant; Fluoxetine; | 2004 |
Adjusted indirect comparison may be less biased than direct comparison for evaluating new pharmaceutical interventions.
Topics: Antidepressive Agents, Second-Generation; Antipsychotic Agents; Bias; Bupropion; Data Interpretation | 2008 |
Psychopharmacology in child and adolescent psychiatry: a review of the past seven years. Part II.
Topics: Adolescent; Alprazolam; Anticonvulsants; Antipsychotic Agents; Anxiety, Separation; Bipolar Disorder | 1995 |
[Antidepressant treatment of schizophrenic patients].
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Depressive Disorder; Drug Therapy, Combination; | 1993 |
13 trials available for fluoxetine and Schizophrenia
| Article | Year |
|---|---|
Treatment of weight gain with fluoxetine in olanzapine-treated schizophrenic outpatients.
Topics: Adolescent; Adult; Analysis of Variance; Benzodiazepines; Double-Blind Method; Female; Fluoxetine; H | 2003 |
A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia.
Topics: Double-Blind Method; Drug Therapy, Combination; Female; Fluoxetine; Fluphenazine; Haloperidol; Human | 1995 |
Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Double-Blind Method; Drug Therapy, Combination; Female | 1994 |
Serum concentrations of clozapine and its major metabolites: effects of cotreatment with fluoxetine or valproate.
Topics: Adult; Clozapine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Comb | 1994 |
Fluoxetine augmentation of clozapine treatment in patients with schizophrenia.
Topics: Adult; Ambulatory Care; Clozapine; Double-Blind Method; Drug Therapy, Combination; Female; Fluoxetin | 1996 |
Interaction between fluoxetine and haloperidol: pharmacokinetic and clinical implications.
Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Drug Interactions; Female; Fl | 1997 |
Pharmacoclinical strategy in neuroleptic resistant schizophrenic patients treated by clozapine: clinical evolution, concentration of plasma and red blood cell clozapine and desmethylclozapine, whole blood serotonin and tryptophan.
Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Brief Psychiatric Rating Scal | 1999 |
Fluoxetine as an adjunct to conventional antipsychotic treatment of schizophrenia patients with residual symptoms.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Double-Blind Method; Drug Administration Schedule; Dru | 2000 |
Effect of fluoxetine and imipramine on the pharmacokinetics and tolerability of the antipsychotic quetiapine.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Antipsychotic Agents; Bipolar Disorder; | 2002 |
Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Double-Blind Method; Drug Therapy, Co | 2002 |
Addition of fluoxetine to treatment of schizophrenic patients.
Topics: Antipsychotic Agents; Drug Therapy, Combination; Fluoxetine; Humans; Male; Psychotic Disorders; Schi | 1991 |
Trial of fluoxetine added to neuroleptics for treatment-resistant schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Clinical Trials as Topic; Depression; Drug Therapy, Combination; Female | 1990 |
Is compulsive drinking a compulsive behavior? A pilot study.
Topics: Adult; Compulsive Behavior; Drinking; Fluoxetine; Humans; Male; Pilot Projects; Schizophrenia; Schiz | 1991 |
51 other studies available for fluoxetine and Schizophrenia
| Article | Year |
|---|---|
Fluoxetine-induced pulmonary hypertension in a patient with schizophrenia.
Topics: Adult; Antidepressive Agents, Second-Generation; Female; Fluoxetine; Humans; Hypertension, Pulmonary | 2014 |
Lower [3H]LY341495 binding to mGlu2/3 receptors in the anterior cingulate of subjects with major depressive disorder but not bipolar disorder or schizophrenia.
Topics: Amino Acids; Animals; Antidepressive Agents; Bipolar Disorder; Brain; Depressive Disorder, Major; Ex | 2016 |
Fluoxetine Adjunctive Therapy for Obsessive-Compulsive Symptoms Associated With Olanzapine in Schizophrenic Patients.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Drug Therapy, Combination; Female; Fluoxetine; Humans; | 2016 |
Nasal bleeding associated with fluoxetine and risperidone interaction: a case report.
Topics: Depression; Drug Interactions; Epistaxis; Fluoxetine; Follow-Up Studies; Humans; Male; Risperidone; | 2009 |
Paraphilias in schizophrenia: differential diagnosis and treatment with selective serotonin reuptake inhibitors.
Topics: Diagnosis, Differential; Fluoxetine; Humans; Male; Middle Aged; Paraphilic Disorders; Schizophrenia; | 2010 |
Raynaud’s phenomenon in a patient with schizophrenia and obsessive-compulsive disorder: a case report.
Topics: Amlodipine; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzodiazepines; Clonaze | 2011 |
Impaired cognitive function and altered hippocampal synapse morphology in mice lacking Lrrtm1, a gene associated with schizophrenia.
Topics: Adaptation, Psychological; Animals; Antipsychotic Agents; Behavior, Animal; Clozapine; Cognition; Di | 2011 |
Fluoxetine and aripiprazole treatment following prenatal immune activation exert longstanding effects on rat locomotor response.
Topics: Acute-Phase Reaction; Amphetamine; Animals; Antipsychotic Agents; Aripiprazole; Disease Models, Anim | 2012 |
Repeated activation of mania by atypical antipsychotics in a patient.
Topics: Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Drug Substitution; Drug Therapy, Combinatio | 2012 |
Serotonin reuptake inhibitor treatment of obsessive-compulsive symptoms in clozapine-medicated schizophrenia.
Topics: Adult; Antipsychotic Agents; Aryl Hydrocarbon Hydroxylases; Clomipramine; Clozapine; Comorbidity; Cy | 2012 |
Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction.
Topics: Adult; Antipsychotic Agents; Depression; Drug Interactions; Drug Therapy, Combination; Female; Fluox | 2002 |
Reply to Dr Mahendran. We have not found reported cases of [obsessive-compulsive] OC arising from de novo with olanzapine treatment.
Topics: Adult; Benzodiazepines; Clomipramine; Fluoxetine; Humans; Male; Obsessive-Compulsive Disorder; Olanz | 2003 |
Electrophysiological effects of acute and chronic olanzapine and fluoxetine in the rat prefrontal cortex.
Topics: Action Potentials; Animals; Benzodiazepines; Depressive Disorder; Dose-Response Relationship, Drug; | 2003 |
Fluoxetine augmentation of haloperidol in chronic schizophrenia.
Topics: Adult; Chi-Square Distribution; Chronic Disease; Drug Synergism; Female; Fluoxetine; Haloperidol; Hu | 2003 |
Obsessive-compulsive symptoms in schizophrenia induced by risperidone and responding to fluoxetine.
Topics: Antipsychotic Agents; Chronic Disease; Fluoxetine; Humans; Male; Middle Aged; Obsessive-Compulsive D | 2003 |
Treatment outcome of schizophrenia co-morbid with obsessive-compulsive disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Comorbidity; Fluoxetine; Huma | 2004 |
Reply to Dr. J-C Shim and colleagues regarding "Fluoxetine augmentation of haloperidol in chronic schizophrenia" [J Clin Psychopharmacol 2003;23:520-521].
Topics: Drug Synergism; Drug Therapy, Combination; Fluoxetine; Haloperidol; Humans; Schizophrenia | 2004 |
Excessive weight gain after remission of depression in a schizophrenic patient treated with risperidone: case report.
Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Bulimia; Depression; Diabetes | 2006 |
A case of fluoxetine-induced syndrome of inappropriate antidiuretic hormone secretion.
Topics: Fluoxetine; Follow-Up Studies; Humans; Inappropriate ADH Syndrome; Male; Middle Aged; Risk Assessmen | 2008 |
Brain serotonin receptors and neuropsychiatric disorders.
Topics: Animals; Brain; Desipramine; Fluoxetine; Humans; Imipramine; Kinetics; Lysergic Acid Diethylamide; M | 1981 |
Delirium: an SSRI-benztropine adverse effect?
Topics: Adult; Age Factors; Aged; Benztropine; Delirium; Drug Interactions; Fluoxetine; Humans; Middle Aged; | 1995 |
[Personality disorders and obsessive-compulsive disorder: critical analysis of the literature data and our studies].
Topics: Clomipramine; Comorbidity; Depressive Disorder; Fluoxetine; Humans; Obsessive-Compulsive Disorder; P | 1995 |
Precipitation of a psychoneuromotor syndrome by fluoxetine in a haloperidol-treated schizophrenic patient.
Topics: Akathisia, Drug-Induced; Drug Therapy, Combination; Fluoxetine; Haloperidol; Humans; Male; Middle Ag | 1994 |
Fluoxetine for the prolonged treatment of schizophreniform psychosis.
Topics: Adult; Drug Therapy, Combination; Female; Fluoxetine; Humans; Long-Term Care; Male; Psychotic Disord | 1995 |
Cyproheptadine in treatment-resistant chronic schizophrenics with prior negative response to fluoxetine.
Topics: Adult; Aged; Antipsychotic Agents; Chronic Disease; Cyproheptadine; Depressive Disorder; Drug Therap | 1994 |
Exacerbation of obsessive-compulsive symptoms associated with clozapine.
Topics: Adult; Clozapine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Comb | 1994 |
Lack of effect of fluoxetine on plasma clozapine concentrations.
Topics: Adult; Clozapine; Drug Interactions; Drug Therapy, Combination; Fluoxetine; Humans; Male; Schizophre | 1994 |
Treatment of obsessive-compulsive symptoms in schizophrenia with a neuroleptic-selective serotonin reuptake inhibitor combination: two case reports.
Topics: Adult; Aged; Antipsychotic Agents; Clomipramine; Drug Therapy, Combination; Fluoxetine; Humans; Male | 1994 |
Treatment of schizophrenia with obsessive-compulsive features with serotonin reuptake inhibitors.
Topics: Adult; Antipsychotic Agents; Drug Therapy, Combination; Fluoxetine; Humans; Male; Obsessive-Compulsi | 1993 |
Fluoxetine for obsessional symptoms in schizophrenia.
Topics: Adult; Female; Fluoxetine; Humans; Obsessive-Compulsive Disorder; Schizophrenia; Schizophrenic Psych | 1994 |
Clozapine, obsessive symptoms, and serotonergic mechanisms.
Topics: Clozapine; Drug Therapy, Combination; Fluoxetine; Humans; Obsessive-Compulsive Disorder; Schizophren | 1993 |
Managing psychotic symptoms when the diagnosis is unclear.
Topics: Adult; Diagnosis, Differential; Fluoxetine; Fluphenazine; Humans; Male; Obsessive-Compulsive Disorde | 1993 |
Development of obsessive-compulsive symptoms during clozapine treatment.
Topics: Adult; Clozapine; Female; Fluoxetine; Humans; Obsessive-Compulsive Disorder; Schizophrenia | 1993 |
Neuroleptic-induced tardive dyskinesia.
Topics: Adolescent; Basal Ganglia Diseases; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Fluoxetine; | 1996 |
Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors.
Topics: 1-Naphthylamine; Adult; Affective Disorders, Psychotic; Aged; Ambulatory Care; Clozapine; Drug Inter | 1996 |
Alterations in plasma dipeptidyl peptidase IV enzyme activity in depression and schizophrenia: effects of antidepressants and antipsychotic drugs.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Dipeptidy | 1996 |
Selective serotonin reuptake inhibitor modulation of clozapine effects on cognition in schizophrenia.
Topics: 1-Naphthylamine; Adult; Antipsychotic Agents; Clozapine; Cognition; Depressive Disorder; Drug Synerg | 1998 |
Effect of fluoxetine on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenia.
Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Biotransformation; Chronic Di | 1998 |
[Severe tardive dyskinesia during treatment with risperidone and fluoxetine].
Topics: Adult; Antipsychotic Agents; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Fluoxetine; Humans | 1998 |
Risperidone for exclusively negative symptoms.
Topics: Adult; Antipsychotic Agents; Drug Administration Schedule; Drug Therapy, Combination; Fluoxetine; Hu | 1999 |
Obsessive-compulsive symptoms with risperidone.
Topics: Antipsychotic Agents; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Fluox | 1999 |
Olanzapine-induced obsessive-compulsive disorder.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clomipramine; Fluoxetine; Humans; Male; Obsessive-Comp | 1999 |
Selective serotonin reuptake inhibitor syndrome: precipitated by concomitant clozapine?
Topics: Antipsychotic Agents; Clozapine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fluoxe | 1999 |
Treating depression in schizophrenia.
Topics: Antidepressive Agents; Antipsychotic Agents; Clozapine; Comorbidity; Depressive Disorder; Drug Inter | 2001 |
Addition of fluoxetine to clozapine.
Topics: Adult; Clozapine; Drug Therapy, Combination; Fluoxetine; Humans; Male; Schizophrenia; Schizophrenic | 1992 |
Possible clozapine exacerbation of bulimia nervosa.
Topics: Acute Disease; Adult; Bulimia; Clozapine; Dyskinesia, Drug-Induced; Female; Fluoxetine; Humans; Recu | 1992 |
Fluoxetine and schizophrenia in a patient with obsessional thinking.
Topics: Adult; Drug Therapy, Combination; Fluoxetine; Humans; Male; Obsessive-Compulsive Disorder; Psychoses | 1992 |
Adjunctive fluoxetine improves global function in chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Compulsive Behavior; Dose-Response Relationship, Drug; | 1990 |
Potential antidopaminergic effects of serotonin reuptake inhibitors.
Topics: Animals; Clomipramine; Dopamine Antagonists; Fluoxetine; Humans; Obsessive-Compulsive Disorder; Rats | 1991 |
Elevation of plasma concentrations of haloperidol after the addition of fluoxetine.
Topics: Adult; Aged; Basal Ganglia Diseases; Drug Interactions; Drug Therapy, Combination; Female; Fluoxetin | 1991 |
Fluoxetine in chronic schizophrenia.
Topics: Amantadine; Chronic Disease; Drug Therapy, Combination; Fluoxetine; Humans; Loxapine; Male; Middle A | 1990 |